Preimplantation Genetic Testing for Aneuploidy (PGTA-A) can be a useful adjunct to IVF treatment. However, in order to make an informed choice if this add on is appropriate for you it is important to have a clear understanding of what it can and can't do.
PGT-A will not increase the chances of having a live birth from treatment
The HFEA rate PGT-A red for improving the chances of having a baby. This is because PGT-A is a selection tool that often reduces the number of embryos available for transfer.
So why bother having it?
There are many other potential advantages for some patients undergoing PGT-A.
PGT-A may reduce the time to successful treatment by ensuring only chromosomally normal embryos are transferred
PGT-A can reduce the chance of miscarriage (associated with chromosomal abnormality) following successful treatment
PGT-A may reduce the overall cost of treatment if less transfers are undertaken
PGT-A may help reduce the burden of treatment for patients
PGT-A may help patients to make informed choices about future treatment by ensuring only embryos with the highest potential are stored
PGT-A may help patients to make choices about stopping treatment or alternatives such as egg donation
The scenarios below show useful patient examples from Cooper Surgical of how PGTA may be beneficial. For FAQ's regarding PGT-A see our blog here
Slides courtesy of Cooper Surgical
Comments